BMBIF News and Press, Bright Minds Biosciences Inc Com From 11/30/21

— Hundreds of de novo patentable psychedelic-based compounds created through discovery program — — Company plans to announce lead molecule in first quarter of 2022 — VANCOUVER, British Columbia, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Bright Minds Bioscienc...

VANCOUVER, British Columbia, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsy...

KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations PR Newswire NEW YORK , Oct. 18, ...

Bright Minds Biosciences Inc. to Webcast Live At VirtualInvestorConferences.com October 14th Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com PR Newswire...

VANCOUVER, British Columbia, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsy...

VANCOUVER, British Columbia, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel drugs for targeted treatment of neurops...

VANCOUVER, British Columbia, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel drugs for targeted treatment of neurops...

-- BMB proprietary 5-HT 2C agonist, BMB-101, shows efficacy in pre-clinical models of Dravet Syndrome/Epilepsy, with lower seizure duration and frequency -- -- Effect of BMB compounds was consistent with other anti-epileptics such as fenfluramine -- VANCOUVER, British Columbia, ...

While the hype around psychedelic stocks and alternative mental health treatments has seemingly cooled over the past few months, the industry is still ripe with opportunity. Long-term investors looking to ride the wave of novel mental health treatments should pay close attention to th...

VANCOUVER, British Columbia, June 16, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel transformative treatments for neuropsych...